deguelin has been researched along with Liver Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdullah, AS; Chen, H; Chen, J; Ho, W; Huang, J; Jiang, J; Kong, L; Liang, B; Liang, H; Liao, W; Liao, Y; Liu, H; Liu, X; Ning, C; Tian, L; Yang, Q; Ye, L; Zang, N; Zhou, B | 1 |
| Choi, JS; Hong, SS; Kim, KW; Lee, DH; Lee, HS; Lee, JH | 1 |
2 other study(ies) available for deguelin and Liver Neoplasms
| Article | Year |
|---|---|
Deguelin inhibits HCV replication through suppressing cellular autophagy via down regulation of Beclin1 expression in human hepatoma cells.
Topics: Antiviral Agents; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Hepacivirus; Hepatocytes; Humans; Liver Neoplasms; Plant Extracts; Rotenone; Virus Replication | 2020 |
Deguelin inhibits human hepatocellular carcinoma by antiangiogenesis and apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chickens; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Rotenone; Vascular Endothelial Growth Factor A | 2008 |